Innovations
The following Emerging Market (“EM”) innovations exemplify the undiscovered treasure chest of potential to be found and commercialized internationally. They have proprietary intellectual property, or could have with additional support, and they have passed proof of concept. Wulff Capital can facilitate introductions, evaluations, regulatory approvals, and deal negotiations.
Rapid Diagnostics
1. Supplier manufactures test kits for pregnancy, HIV, malaria, syphilis, diabetes, prostrate cancer and illegal drugs. These 
products retail for under $1, and are manufactured under strict ISO 13485:2003 conditions. These in-vitro diagnostic test kits, are based on lateral flow technology, and use a stable, protein-gold complex in an electrolyte-infused colloid suspension.
2. A patented flow cytometer technology that requires no sheath fluid permits small samples, has low operating costs, rapid set-up, and is easy to maintain. The system is adapted for efficient and cost-effective counting of CD4 and CD8 T-cells (HIV/AIDS) in remote areas of the world.
3. A haematology device that analyses CD4 count for $0.25-0.50 per test has car battery-powered portability, and uses flow cytometry with gold reagent, proprietary software and inkless printer. A sealed vial process protects testing technician.
4. Immunochromatography tests that detect specific pathogens in global food supply. The patented technology platform’s first product is for Lawsonia intracellularis, the leading cause of Ileitis in swine. Development and evaluation have been completed.
5. Kits using materials indigenous to India are being commercialized for HIV, hepatitis C and cysticercosis. Kits are in development for TB, leishmania infection, malaria, HLA and typhoid.
6. Test kits for Chlamydia include a patented disposable urine collection device. The proprietary signal amplification platform uses nano-gold reagents, and is being developed for hepatitis B and HIV detection for use in resource-limited settings.
7. Portable probes that diagnose eye diseases, uses the ophthalmic ultrasound technology of a global leader in the field. The 
system converts a personal computer into a freestanding system for remote use of hand-held probes. FDA 510-k approval was granted in January 2008.
8. A lab-on-a-chip that diagnoses HIV at point of care, is handheld, battery-operated, and can be reprogrammed for coronary, cancer and infectious diseases by changing the system's molecular-level code. Three sets of clinical trials are ongoing.
9. A hand-held ophthalmoscope that diagnoses multiple diseases, including hypertension, septicaemia and diabetes. It uses a retinal camera, proprietary software and disease pattern database.
10. A tuberculosis test is in clinical trial in Africa, in partnership with FIND (Foundation for Innovative New Diagnostics, Geneva, Switzerland).